The nucleoside analog cytarabine (Ara-C) is an essential component of primary and salvage chemotherapy regimens for acute myeloid leukemia (AML). After cellular uptake, Ara-C is converted into its therapeutically active triphosphate metabolite, Ara-CTP, which exerts antileukemic effects, primarily by inhibiting DNA synthesis in proliferating cells 1 . Currently, a substantial fraction of patients with AML fail to respond effectively to Ara-C therapy, and reliable biomarkers for predicting the therapeutic response to Ara-C are lacking 2, 3 . SAMHD1 is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase that cleaves physiological dNTPs into deoxyribonucleosides and inorganic triphosphate 4, 5 . Although it has been postulated that SAMHD1 sensitizes cancer cells to nucleoside-analog derivatives through the depletion of competing dNTPs 6 , we show here that SAMHD1 reduces Ara-C cytotoxicity in AML cells. Mechanistically, dGTP-activated SAMHD1 hydrolyzes Ara-CTP, which results in a drastic reduction of Ara-CTP in leukemic cells. Loss of SAMHD1 activity-through genetic depletion, mutational inactivation of its triphosphohydrolase activity or proteasomal degradation using specialized, virus-like particles 7, 8 -potentiates the cytotoxicity of Ara-C in AML cells. In mouse models of retroviral AML transplantation, as well as in retrospective analyses of adult patients with AML, the response to Ara-C-containing therapy was inversely correlated with SAMHD1 expression. These results identify SAMHD1 as a potential biomarker for the stratification of patients with AML who might best respond to Ara-C-based therapy and as a target for treating Ara-C-refractory AML.
The current backbone of AML therapy is treatment with the cytidine analog Ara-C and the anthracycline daunorubicin. Despite a high rate of initial remissions, a substantial fraction of patients with AML relapse and acquire resistance to Ara-C 1, 9 . The prognosis of patients with AML, especially elderly individuals, remains dismal 2, 9 . Mutations in the SAMHD1 gene, which encodes sterile alpha motif and histidine-aspartic domain-containing protein 1 (SAMHD1), have been associated with Aicardi-Goutières autoimmune syndrome 10 and the development of malignancies that include cutaneous T cell lymphoma, chronic lymphatic leukemia and colon cancer [11] [12] [13] . SAMHD1, a dNTP triphosphohydrolase that cleaves dNTPs into deoxyribonucleosides and inorganic triphosphate, enhances the efficacy of certain nucleoside-analog drugs for the treatment of human immunodeficiency virus type 1 (HIV-1) by decreasing the levels of intracellular dNTPs 14, 15 , which apparently compete with the thymidine analog triphosphates for incorporation into HIV-1 complementary DNA (cDNA) during reverse transcription 16 . We postulated that SAMHD1 could have a similar effect on nucleoside-analog-based therapy for leukemia 6 .
To investigate whether SAMHD1 expression influences Ara-C cytotoxicity in AML cells, we tested whether Ara-C sensitivity in 13 AML cell lines, determined by the half-maximal inhibitory concentration (IC 50 ), is correlated with SAMHD1 protein and SAMHD1 mRNA levels. Both SAMHD1 expression ( Fig. 1a and Supplementary  Fig. 1 ) and Ara-C sensitivity (Supplementary Table 1 ) varied considerably among these cell lines. Unexpectedly, SAMHD1 protein and mRNA levels were inversely correlated with Ara-C cytotoxicity (P = 0.0037; Fig. 1b and Supplementary Fig. 2a,b) , as well as with the levels of early (caspase 3 and 7 activity; P = 0.02; Supplementary  Fig. 3a,b) and late (sub-G1 cells, apoptotic DNA fragmentation; P = 0.029; Supplementary Fig. 3c,d ) markers of apoptosis. By contrast, no significant correlation could be established between Ara-C IC 50 values and the expression of cellular proteins previously implicated in Ara-C uptake or its conversion to Ara-CTP 1 , including equilibrative nucleoside transporter (SLC29A1, also known as ENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), deoxycytidylate deaminase (DCTD) or 5′-nucleotidase (NT5C2) (Fig. 1a,c-g ).
To further investigate the role of SAMHD1 in Ara-C resistance, we tested the effects of SAMHD1 deficiency by taking a number of approaches: (i) depletion of SAMHD1 in AML cell lines expressing high endogenous SAMHD1 levels, by using either lentiviral vectors encoding SAMHD1-specific shRNA or transfection with SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia SAMHD1-specific siRNA; (ii) CRISPR-Cas9-mediated disruption of the SAMHD1 gene; and (iii) targeted degradation of SAMHD1 by using virus-like particles (VLPs) that shuttle the SAMHD1-interacting lentiviral Vpx protein (Vpx-VLPs) into cells 7, 8, 17 ( Fig. 2a and Supplementary Fig. 4 ). Vpx recruits SAMHD1 to a cullin4A-RING E3 ubiquitin ligase (CRL4 DCAF1 ), which targets the enzyme for proteasomal degradation 7, 8 .
SAMHD1 depletion in AML cell lines (OCI-AML3 and THP-1) by RNA interference, SAMHD1 knockout (THP-1 KO) or transduction with Vpx-VLPs (MonoMac6 cells and THP-1) markedly sensitized AML cell lines to Ara-C toxicity relative to the respective controls (Fig. 2a,b and Supplementary Fig. 4) . By contrast, SAMHD1-specific siRNA had only a marginal effect on Ara-C toxicity in low-SAMHD1-expressing parental HEL cells (Fig. 2a,b) . Notably, we observed SAMHD1 dependency, although less pronounced, for the purine analog fludarabine ( Supplementary Fig. 5a) ; however, the IC 50 values for the topoisomerase II inhibitors etoposide and daunorubicin, as well as for dFdC (2′,2′-difluorodeoxycytidine, also known as gemcitabine), were not consistently affected by SAMHD1 protein downmodulation ( Supplementary  Fig. 5b-d) , which indicates a certain degree of drug specificity.
In HEL cells, an AML cell line that expresses very low endogenous levels of SAMHD1 (Figs. 1a and 2a,c) , constitutive overexpression of wild-type SAMHD1 (SAMHD1-WT), but not of the dNTPase-deficient SAMHD1 D311A mutant, markedly increased the IC 50 values for Ara-C and, to a lesser extent, fludarabine ( Fig. 2c and Supplementary Fig. 5a ). By contrast, the toxicities of daunorubicin, etoposide or dFdC were largely unaltered (Supplementary Fig. 5b-d) . These results indicate that the enzymatic activity of SAMHD1 is critically involved in mediating the resistance of AML cells to Ara-C, and to a lesser extent, to fludarabine. Notably, Ara-C at concentrations mimicking the steady-state levels of Ara-C in plasma during standard Ara-C regimens (100-200 mg/m 2 ) 1 or the minimum blood plasma concentration (C min ; achieved 12 h after the completion of intravenous (i.v.) infusion) during high-dose Ara-C therapy (3,000 mg/m 2 ) 18 only partially affected the viability of SAMHD1-expressing AML cell lines, whereas SAMHD1-depleted cells were effectively killed at these concentrations (Supplementary Fig. 6 ).
Although previous studies in vitro provided no evidence that triphosphorylated anti-viral nucleoside analogs can be hydrolyzed by SAMHD1 (refs. 19,20) , we hypothesized that SAMHD1 might be able to hydrolyze Ara-CTP, which differs from the physiological dCTP substrate by only a hydroxyl substituent in the up position at carbon atom 2 of the pentose moiety (Supplementary Fig. 7 ). To test directly whether Ara-CTP is hydrolyzed by SAMHD1, we quantified Ara-CTP levels relative to SAMHD1 expression after short-term exposure of AML cells to 13 C 3 -Ara-C by using liquid chromatography tandem mass spectrometry (LC-MS/MS). We detected Ara-CTP levels in SAMHD1-deficient THP-1 KO cells that were 47-fold higher than those in THP-1 control cells, whereas SAMHD1 deficiency did not affect dFd-CTP levels after drug treatment (Supplementary Fig. 8 ). Moreover, HEL SAMHD1-WT cells harbored 97-and 69-fold lower levels of Ara-CTP than those in parental HEL cells and HEL cells expressing the SAMHD1 D311A mutant, respectively (Fig. 2d) . Notably, the lack of enzymatically active SAMHD1 in THP-1 KO cells or in parental and SAMHD1 D311A -expressing HEL cells also resulted in elevated dNTP levels ( Supplementary Fig. 9a,b) , which, however, did not counteract the cytotoxicity of the concomitantly increased Ara-CTP levels (Fig. 2b,c) .
dGTP or GTP binding to the primary allosteric site of SAMHD1 leads to the formation of a catalytically active tetramer, whereas the second allosteric site of the enzyme accommodates dNTPs [21] [22] [23] . To elucidate whether Ara-CTP can serve as a substrate or as both an activator and substrate for the triphosphohydrolase, we performed an enzymatic in vitro assay using bacterially expressed, full-length SAMHD1. Analysis of reaction products by ion-pair reverse-phase high-performance liquid chromatography (HPLC) revealed that SAMHD1 hydrolyzes Ara-CTP to Ara-C, which requires the presence of the activator dGTP, which itself is also cleaved to dG (Fig. 2e) . In specificity control experiments, the physiological substrate TTP, but not dFd-CTP, was hydrolyzed by SAMHD1 ( Supplementary  Fig. 10a,b) . Thus, Ara-CTP is a direct substrate, but not an activator, of SAMHD1's triphosphohydrolase activity in AML cells.
To explore whether SAMHD1 might contribute to the development of Ara-C resistance, we gradually adapted three AML cell lines (HEL, HL-60 and Molm13), characterized by low endogenous SAMHD1 expression levels and high Ara-C sensitivity, to growth in the presence of the nucleoside analog. The resulting drug-resistant sublines (designated r Ara-C 2 µg ) were cultivated in medium containing Ara-C at a concentration of 2 µg/ml, and they displayed increases in Ara-C IC 50 , values ranging from 1,643-to 4,250-fold relative to the parental cell lines (Supplementary Table 2 ). In addition to changes in the expression of some cellular factors previously implicated in acquired Ara-C . Expression levels were normalized to β-actin and are shown as arbitrary units (a.u.); the relative expression of each protein in THP-1 cells was set to 1. For b-g, closed circles and error bars represent means ± s.e.m. of three independent experiments, each performed using technical replicates (n = 3). Data in b-g were analyzed using a linearregression model. r 2 values indicate goodness of fit of the regression model to the data, and represent variance explained by the independent variable divided by total variance of the IC 50 Ara-C values. Statistical analyses were performed using unpaired two-tailed Students' t test.
resistance (i.e., DCK, CDA and NT5C2), the levels of SAMHD1 were markedly increased in the Ara-C-resistant sublines relative to their parental counterparts ( Fig. 3a and Supplementary Fig. 11 ). Ara-C resistance was accompanied by drastically decreased Ara-CTP levels (Fig. 3b) , and the exposure of Ara-C-resistant AML cells to Vpx-VLPs depleted SAMHD1, increased Ara-CTP levels, and resensitized the cells to Ara-C by up to 11.5-fold relative to Vpr-VLP-treated control cells (Fig. 3c,d ). Whereas cultivation of the parental AML cell lines in the presence of the drug for 24 h did not acutely induce SAMHD1 levels ( Supplementary Fig. 12a) , cultivation of Molm13 cells in the presence of the drug for 20 d resulted in an upregulation of SAMHD1 levels as compared to parental cells (Supplementary Fig. 12b ). To study the role of SAMHD1 in AML drug sensitivity in vivo, we transformed mouse myeloid progenitor cells using the oncogenes Hoxa9 and Meis1 or Mn1 and subsequently deleted the Samhd1 gene using CRISPR-Cas9 genome editing with two independent guide RNAs (gRNAs). SAMHD1 WT control (SAMHD1 WT) AML blasts and knockout (SAMHD1 KO) AML blasts were transplanted into irradiated recipient mice and were treated with either Ara-C or phosphate-buffered saline (PBS) on days 18 and 19 after transplantation (Supplementary Fig. 13a-d) . The overall survival of the two independent mouse cohorts transplanted with SAMHD1 KO AML cells was prolonged dramatically as compared to mice transplanted with SAMHD1 WT AML cells by administration of Ara-C (Fig. 4a,b (P = 2.97 × 10 −6 for both cohorts), Supplementary Fig. 13e (P = 3.05 × 10 −6 ) and Supplementary Fig. 13f (P = 4.32 × 10 −6 )), but not by PBS treatment (Fig. 4a,b and Supplementary Fig. 13e,f) . Similar results were obtained for two mouse cohorts for which a second Samhd1 gRNA was used (Supplementary Fig. 14) .
In human blasts isolated from the bone marrow of patients with therapy-naive AML, basal SAMHD1 expression was correlated with Ara-C IC 50 values (P = 0.04; Supplementary Fig. 15 ). Moreover, we tested the effects of transient depletion of SAMHD1 in blasts of six patients (Supplementary Table 3 ; patients A to F). 2 d after transfection with control or SAMHD1-targeting siRNA, the blasts were cultured in the presence of Ara-C or daunorubicin. SAMHD1 depletion diminished Ara-C IC 50 values by 3-to 15-fold (Fig. 4c) , whereas the sensitivity of the blasts to daunorubicin was unaltered (Supplementary Table 4 ). Similarly, treatment with SAMHD1-degrading Vpx-VLPs sensitized primary AML blasts to Ara-C, but not to daunorubicin, as compared to Vpr-containing control VLPs (Supplementary Fig. 16 and Supplementary Table 5 ). Concomitantly with this sensitization, intracellular Ara-CTP levels were elevated (Supplementary Fig. 8c,d) .
Finally, we examined the suitability of SAMHD1 expression as a biomarker for predicting the response of AML to standard Ara-Ccontaining therapy. We analyzed an AML cohort of 150 adult patients who had received one to two courses of Ara-C-containing induction therapy in two university-hospital study centers in Germany. Patients received either two cycles of "7 + 3" or "7 + 3" plus high-dose Ara-C in combination with mitoxantrone (HAM), according to standard German AML protocols (Supplementary Table 6 ). The "7 + 3" treatment regime refers to 7 d of standard-dose Ara-C, with the addition of daunorubicin for 3 d during the 7-d-chemotherapy induction cycle (see Online Methods). Retrospective analysis of SAMHD1 protein levels by immunohistochemical (IHC) staining of blasts in sections of paraffinized bone marrow isolated at primary diagnosis revealed that the expression of SAMHD1 was highly variable between patients, and importantly, that it was markedly increased in the group of patients with AML that did not achieve complete remission ('no CR'; n = 38) at the end of induction therapy, as compared to the group of patients with documented complete remission ('CR'; n = 112) (P = 6.3 × 10 −8 , Wilcoxon rank-sum test) (Fig. 4d,e and Supplementary Table 6) . Of the 150 patients, 112 achieved CR; of these, 90 were scored as 'SAMHD1 low' and 22 were scored as 'SAMHD1 high' . The CR rate in the SAMHD1-high cohort was 22/50 (44%), whereas the CR rate in the SAMHD1-low cohort was 90/100 (90%). This difference between the two SAMHD1-stratified cohorts was highly statistically significant (P = 3.477 × 10 −9 by chi-squared test with 1 degree of freedom). As a validation of the IHC staining and scoring system, levels of SAMHD1 protein expression in blasts, as determined by IHC scoring and, in parallel, by flow cytometry, showed a positive correlation (P < 0.0001; Supplementary Fig. 17 ). All CR patients received post-remission therapy consisting of either a high-dose, Ara-C-containing chemoconsolidation regimen and/or allogeneic stem cell transplantation. In our AML cohort, the level of SAMHD1 expression in blasts at initial diagnosis was highly predictive for event-free survival (EFS) (P = 1.86 × 10 −11 ; Fig. 4f) , in which an event was defined as failure to achieve CR, relapse or death. Also, relapse-free survival (RFS) of CR patients was significantly worse in the SAMHD1-high than in the SAMHD1-low patients (P = 2.02 × 10 −4 , Fig. 4g ), which indicates that the depth of remission in SAMHD1-high patients was less pronounced than in SAMHD1-low patients. Although the median observation time was relatively short, SAMHD1-high patients showed significantly worse overall survival (OS) (P = 4.85 × 10 −3 ; Fig. 4h ). When patients were censored from the analyses at the time of allogeneic transplantation, all differences (EFS, RFS and OS) remained statistically significant (P = 9.82 × 10 −6 ; P = 6.81 × 10 −5 ; and P = 2.28 × 10 −3 , respectively) ( Supplementary Fig. 18a-c) . Notably, no correlation could be established between cytogenetic risk groups and SAMHD1 expression (Supplementary Fig. 19a) . In a multivariate analysis that included age, gender, initial leukocyte count and cytogenetic risk group and type of second induction cycle (HAM versus "7 + 3"), high SAMHD1 expression proved to be an independent risk factor for EFS (hazard ratio 1.72; P = 5.23 × 10 −8 ) and OS (1.33; P = 0.0228) ( Supplementary  Fig. 19b,c) .
Furthermore, mining of the publicly available AML data set of The Cancer Genome Analysis (TCGA) cohort 24 confirmed a correlation of low SAMHD1 mRNA expression with CR for patients who had received an Ara-C-containing therapy (Supplementary Fig. 20) . Thus, SAMHD1 levels at diagnosis are inversely correlated with the Figure 4 SAMHD1 expression in leukemic blasts predicts response to Ara-C-containing therapy in mouse models of AML transplantation and patients with AML. (a,b) Kaplan-Meier survival analyses of Hoxa9/Meis1-(a) or Mn1-driven (b) AML transplantation models by using myeloid progenitors with endogenous SAMHD1 expression (SAMHD1 WT) or SAMHD1-deleted (SAMHD1 KO) myeloid progenitors. Ara-C, i.p. administration of 75 mg/kg Ara-C on days 18 and 19 after transplantation; PBS (control i.p. treatment). The difference in overall survival between Ara-C-treated SAMHD1 WT and SAMHD1 KO AML mice was statistically significant (log-rank test, Hoxa9/Meis1, P = 2.97 × 10 −6 ; n = 10 both groups; Mn1, P = 2.97 × 10 −6 ; n = 10 both groups). The differences between the two PBS-treated groups and between Ara-C-treated SAMHD1 WT AML mice and both PBS-treated groups were not significant (Hoxa9/Meis1, P = 0.42; SAMHD1 KO (n = 10) versus SAMHD1 WT (n = 9); Mn1; P = 0.196; n = 10 both groups). (c) Blasts isolated from bone marrow from six adult patients with AML (A-F) were transfected with SAMHD1-specific or control siRNAs, and 2 d later, were analyzed for Ara-C cytotoxicity (top) and SAMHD1 expression (bottom). Ara-C IC 50 values are presented as the means ± s.d. of the triplicates shown. The numbers above the data points indicate the factor of difference between the siCTRL and siSAMHD1 groups. Uncropped images are shown in Supplementary Figure 25 . (f-h) Kaplan-Meier analyses for event-free survival (f), relapse-free survival (g) and overall survival (h), for which patients with AML were grouped into 'no or low SAMHD1 expressors' (IHC scores 0 or 1; red curves) and 'high SAMHD1 expressors' (IHC scores 2 or 3; black curves). Numbers above the plots indicate the absolute number of patients in each of the two groups at the respective time points. Significance of difference between survival curves in f,g and h was assessed using the log-rank test (P values indicated in figure; *P ≤ 0.05, **P < 0.01, ***P < 0.001).
clinical response to Ara-C-based therapy in two different cohorts of adult patients with AML, and this prominent role of SAMHD1 in Ara-C response is corroborated by results from mouse models of AML transplantation.
Taken together, this study identifies SAMHD1 as a cellular biomarker for the stratification of patients to Ara-C-based therapy and uncovers a patient-and drug-specific interference mechanism ( Supplementary Fig. 21 ) that, in addition to established molecular and cytogenetic risk factors 25 , determines the outcome of AML disease. Ara-C's mimicry of the physiological nucleoside cytidine endows it with antileukemic activity, but this mimicry is detrimental in AML blasts that express the Ara-CTP-inactivating SAMHD1 protein. This concept applies to a lesser extent also to the purine analog fludarabine, but not to dFdC, which indicates that SAMHD1 should be considered a crucial cellular factor in the evaluation of all nucleoside-analogbased drugs or drug candidates to treat AML. Future studies will determine whether protein-or mRNA-based quantification of SAMHD1 in AML blasts at diagnosis is a better predictor of the therapeutic response. In vivo strategies aimed at transient downregulation of SAMHD1 by either RNA interference or application of SAMHD1-degrading Vpx-VLPs, or, conceivably, through the administration of an inhibitor of SAMHD1's enzymatic activity, might improve the Ara-C-based treatment of AML and other malignancies.
MeTHoDS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Generation of Ara-C-resistant cell lines. Ara-C-resistant cell lines were established by the continuous exposure of Ara-C sensitive cell lines HL-60, HEL, Molm13, THP-1, MV4-11 and OCI-AML3 to increasing drug concentrations, as previously described 31, 32 , and are part of the Resistant Cancer Cell Line (RCCL) collection (http://www.kent.ac.uk/stms/cmp/RCCL/ RCCLabout). Briefly, cells were cultured at increasing Ara-C concentrations, starting with concentrations that inhibited the viability of the parental cell lines by 50% (IC 50 ). Ara-C concentrations were doubled every 2 to 6 weeks until cells readily grew in the presence of 2 µg of Ara-C. Resistant cell lines were designated as HL-60 r Ara-C 2 µg , HEL r Ara-C 2 µg , Molm13 r Ara-C 2 µg , THP-1 r Ara-C 2 µg , MV4-11 r Ara-C 2 µg and OCI-AML3 r Ara-C 2 µg and were cultured in the presence of 2 µg Ara-C. Cells were routinely tested for mycoplasma contamination (LT07-710, Lonza) and authenticated by shorttandem-repeat profiling 27 .
Cell-viability assay. The viability of AML cell lines treated with various drug concentrations was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay after 96 h of incubation, as described previously 33 . IC 50 values were determined using CalcuSyn (Biosoft).
Cytotoxic assay for AML blasts ex vivo. The cell viability of AML blasts was determined after 96 h of incubation by the quantification of ATP levels in cell-culture supernatants using the CellTiter-Glo Luminescent Cell Viability Assay (G7573, Promega) according to the manufacturer's instructions. Luminescence was measured on a Tecan infinite M200 (TECAN) instrument at a wavelength of 560 nm (reference wavelength 620 nm). IC 50 values were determined using CalcuSyn (Biosoft).
Apoptosis assays. Sub-G1 cells, as a marker for DNA fragmentation in late apoptotic cells, were measured according to Nicoletti by flow cytometry 34 . Briefly, Ara-C-treated and untreated cells were washed once in 1× PBS, incubated for at least 2h at 4 °C with Nicoletti buffer (0.1% trisodiumcitratedihydrate pH 7.4, 0.1% Triton X-100, 50 µg/ml propidium iodide), and diluted before measurement in 1× PBS. Samples were analyzed using a FACSVerse (BD Biosciences) and FlowJo software (TreeStar). Alternatively, caspase 3/7 activity, as a surrogate for early apoptosis, was quantified by luminescence. Briefly, Ara-C-treated and untreated cells were measured using the CaspaseGlo 3/7 assay (G8091, Promega) according to the manufacturer's instructions. Luminescence was measured on a Tecan infinite M200 (TECAN) instrument at a wavelength of 560 nm (reference wavelength 620 nm).
Flow cytometry. Intracellular SAMHD1 staining was performed as previously described 15 For in vitro characterization of Hoxa9/Meis1-and Mn1-transformed myeloid progenitor cells, surface-marker expression was characterized by flow cytometry using a LSRFortessa flow cytometer (BD Biosciences). Briefly, cells (2 × 10 5 ) were washed twice with 2% FCS in PBS and stained with the following antibodies: PerCP-Cy5.5-conjugated anti-mouse Gr1 (45-5931), V450-conjugated anti-mouse Mac1 (48-0112), APC-conjugated anti-mouse c-kit (17-1171), PE-Cy7-conjugated anti-mouse Sca1 (25-5981), PE-conjugated anti-mouse FcεRI (12-5898, all from eBioscience) and APC-H7-conjugated anti-mouse CD19 (560245, BD Bioscience). 7-AAD (BD-Bioscience) was used for the exclusion of dead cells.
Immunoblotting. Cells were lysed in Triton X-100 sample buffer and proteins separated by sodium dodecyl sulfate-PAGE. Proteins were blotted
